Loading…

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

Background We evaluated the efficacy of gemcitabine and carboplatin for patients affected by pretreated metastatic breast cancer. A subgroup analysis was performed to evaluate the predictive value of immunohistochemically defined breast cancer subtypes. Methods We included human epidermal growth fac...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2013-04, Vol.18 (2), p.343-349
Main Authors: Nelli, Fabrizio, Moscetti, Luca, Natoli, Guido, Massari, Annalisa, D’Auria, Giuliana, Chilelli, Mario, Fabbri, Maria Agnese, Frittelli, Patrizia, Ruggeri, Enzo Maria
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background We evaluated the efficacy of gemcitabine and carboplatin for patients affected by pretreated metastatic breast cancer. A subgroup analysis was performed to evaluate the predictive value of immunohistochemically defined breast cancer subtypes. Methods We included human epidermal growth factor 2 (HER-2) negative metastatic breast cancer resistant to previous anthracycline-based and taxane-based chemotherapy, and HER-2 positive metastatic breast cancer with at least two progressions of disease during protracted trastuzumab-based therapy. Treatment consisted of gemcitabine (1000 mg/m 2 intravenous (iv) on days 1 and 8) and carboplatin (area under the curve 5 iv on day 1) applied every 3 weeks. Results Forty-two patients were registered. Disease control was 58%, with a median time-to-progression (TTP) of 7 months (range 1–12) and a median overall survival of 10.5 months (range 1–34). Patients were grouped as triple negative (ER and PR negative, HER-2 negative), HER-2 (HER-2 positive, ER and PR negative), luminal B (ER and/or PR positive and either HER-2 positive and/or high Ki67), and luminal A (ER and/or PR positive and HER-2 negative and low Ki67). For luminal A patients, disease control was lower (luminal A 34 vs. others 67%; P  = 0.02), TTP was shorter (luminal A 2.4 months vs. others 6.3 months, P  = 0.015), and overall survival was shorter (luminal A 7.5 months vs. others 11.7 months, P  = 0.034) than for other subtypes. Conclusions Gemcitabine and carboplatin are effective for pretreated patients with metastatic breast cancer. Luminal A subtype seems to fare poorly compared with other subtypes. Specific difference in gene expression might account for the different outcome.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-012-0384-x